Related by context. All words. (Click for frequent words.) 73 preclinical efficacy 68 rxRNA 67 CRLX# 67 vivo validation 66 Phase IIb clinical trials 66 PORxin TM 66 cannabinor 66 Kahalalide F 66 vivo preclinical studies 66 demonstrated antitumor activity 66 BrachySil TM 66 PSMA ADC 65 generation URAT1 inhibitor 65 preclinically 65 orally dosed 65 therapeutic monoclonal antibody 65 vivo pharmacology 65 novel peptide 65 epigenetic therapies 65 Omacetaxine 65 CD# CEA 65 including eniluracil ADH 65 prokinetic agent 65 NOX E# 65 Bayer HealthCare Onyx Pharmaceuticals 65 Prodarsan R 65 GRNVAC1 65 cGMP manufacture 65 Pertuzumab 65 fosbretabulin 65 AKT inhibitor 65 PEGylated interferon 65 ENMD # 64 vitro ADME 64 LEAPS TM 64 proprietary PEGylation 64 pharmacokinetic pharmacodynamic 64 ospemifene 64 PD LID 64 GLP toxicology studies 64 tubulin inhibitor 64 nucleotide analog 64 Guanilib 64 multicenter Phase II 64 Biomerk Tumorgrafts 64 DEEP AF 64 CYT# potent vascular disrupting 64 huN# DM1 64 predictive toxicology 64 Myocet 64 metabolite profiling 64 DEB# 64 HuMax CD#b 64 Phase 1b clinical trials 64 oral prodrug 64 PI3K/Akt pathway inhibitor 64 cyclophilin inhibitors 64 HGS# 64 acyclovir Lauriad R 64 PORxin TM platforms 64 xenograft mouse 64 Phase IIa trials 64 oral proteasome inhibitor 64 evaluating mipomersen 64 ChronVac C R 64 HDL Mimetic Peptide 64 nanopharmaceutical 64 cMET 64 next generation URAT1 64 targeted radiotherapeutic 64 GAMMAGARD 64 Oral NKTR 64 PET tracers 63 potent suppressor 63 Panzem R NCD 63 Phase Ib study 63 galiximab 63 Monoclonal antibody 63 Trofex 63 SoftScan ® 63 human tumor xenograft 63 external counterpulsation systems 63 Squalamine 63 kidney urologic 63 Phase 2a clinical trials 63 transgenic mouse models 63 Spiegelmer 63 Erimos 63 XTEN 63 OMP #M# 63 SAR# [002] 63 Angiotensin Converting Enzyme 63 NurOwn 63 EGS# 63 renin inhibitors 63 PEG SN# 63 Phase Ib II 63 pharmacodynamic PD 63 TBC# 63 histone deacetylase inhibitor 63 mg kg BID 63 Phase 1a clinical 63 YONDELIS R 63 JAK inhibitors 63 OvaRex R 63 vivo toxicology 63 Reports Preclinical Data 63 telomerase therapeutic 63 Safinamide 63 ImmunoVEX 63 IL# PE#QQR 63 human microdosing 63 hyaluronidase enzyme 63 Septin9 63 favorable pharmacokinetic profile 63 orally inhaled migraine 62 ALK inhibitors 62 nonclinical studies 62 kinase profiling 62 vidofludimus 62 Onconase 62 multicenter clinical trials 62 LungSign TM 62 IDO inhibitor 62 PDE# inhibitors 62 personalized dendritic 62 Vaxfectin TM 62 JAK2 inhibitor 62 relapsed MM 62 LymphoStat B TM 62 Phase Ib clinical 62 PHX# 62 biostatistical analysis 62 anti fibrotic 62 MCSP respectively 62 LungAlert TM 62 IIa clinical 62 volociximab 62 ESBA# 62 PDE4 inhibitor 62 hereditary emphysema 62 Pimavanserin 62 omega interferon 62 AAG geldanamycin analog 62 radezolid 62 MEK inhibitor 62 HDL Selective Delipidation 62 YONDELIS 62 oncolytic virus therapies 62 CBLC# 62 nucleoside tide 62 TriGrid 62 REVIVE Diabetes 62 ocular formulation 62 potently inhibit 62 oral picoplatin 62 mGluR2 NAM 62 Aeolus Pharmaceuticals Announces 62 opto acoustic 62 Hsp# Inhibitor 62 NASDAQ CGEN announced 62 drug GAP #B# 62 Initiates Enrollment 62 antisense inhibitors 62 Solazed 62 Exelixis compounds 62 novel histone deacetylase 62 Theranostics 62 Panzem R 62 XL# anticancer compounds 62 immunotherapeutic vaccine 62 Interferon beta 62 2 methoxyestradiol 62 Thiarabine 62 xenograft models 62 phenotyping 62 Initiates Clinical 62 ONCONASE R 62 preclinical toxicology 62 NuroPro R 62 anti Parkinsonian 62 HuCAL antibodies 62 liposomal formulation 62 TEMSO 62 acetonide FA 62 intranasal formulation 62 BrachySil 62 BHT DNA 62 vinca alkaloid 62 ZFN modified 62 generation purine nucleoside 62 preclinical 62 Xenograft 62 vivo assays 62 Elagolix 62 Tesmilifene 62 NOD SCID mice 62 OncoVex 62 Hedgehog Pathway Inhibitor 62 OvaRex MAb 62 pharmacodynamic parameters 62 TRV# [001] 62 LAB CGRP 62 Azedra 62 alvespimycin 62 Initiates Clinical Trial 61 TÎ ² 4 61 Aflibercept 61 Presents Preclinical Data 61 R#/MEM # 61 cardiac perfusion 61 eTag assays 61 RGB # 61 Alequel ™ 61 Prodarsan ® 61 THR beta agonist 61 molecular imaging radiopharmaceutical 61 DiLA2 61 telomerase activator 61 AQUA ® 61 miRview ™ mets 61 entinostat 61 CG# [003] 61 antiangiogenic activity 61 Temsirolimus 61 orally administered inhibitor 61 Anticalins R 61 Daclizumab 61 cediranib 61 PrevOnco ™ 61 biomarker assays 61 p# inhibitor 61 TLR antagonists 61 pharmacokinetic PK study 61 Tyrosine Kinase Inhibitor 61 paclitaxel poliglumex 61 Nasdaq CGEN 61 sodium thiosulfate STS 61 uricase 61 Tumor Response 61 vitro pharmacology 61 PET tracer 61 antimitotic 61 DXL# 61 DermaVir Patch 61 multicenter Phase III 61 sarcoma melanoma 61 gastrointestinal disorders ATI 61 VersaFilm 61 aldehyde dehydrogenase ALDH2 deficiency 61 oral talactoferrin 61 DNA methylation markers 61 Ostabolin C TM 61 Micromet BiTE 61 delipidation 61 novel therapeutic antibodies 61 Cumulase 61 isoform selective 61 ChronVac C ® 61 Phase #b/#a clinical 61 Soliris eculizumab 61 NP2 Enkephalin 61 PRLX # 61 Archexin 61 RNAi Therapeutic 61 NABTT 61 resolvin 61 investigational protease inhibitor 61 Homspera ® 61 Preclinical studies suggest 61 novel VDA molecule 61 CORT # 61 depsipeptide 61 metabolite identification 61 non nucleoside inhibitor 61 CellCiphr 61 preclinical pharmacokinetic 61 Capesaris 61 Adnectin 61 confirmatory clinical 61 trodusquemine 61 Cardiotoxicity 61 Solazed TM 61 Pharmacokinetics PK 61 NB S# strontium malonate 61 p# MAP kinase inhibitor 61 GeneICE 61 XOMA 3AB 61 INxin TM 61 XmAb 61 Quinamed 61 blinded randomized placebo controlled 61 HepDirect prodrug 61 Alferon N 61 HTS assay 61 multitargeted 61 Peptidomics 61 Initiate Clinical Trial 61 Deforolimus 61 AFREZZA TM 61 Mipomersen 61 Blinatumomab 61 FOLOTYN ® 61 pharmacodynamic properties 61 HQK 61 virosome 61 Zalypsis 61 topically administered 61 mertansine 61 deforolimus 61 selective estrogen receptor modulator 61 trastuzumab DM1 T DM1 61 Charlesson 61 pharmacokinetic pharmacodynamic PK PD 61 B2A 61 synthetic retinoid 61 histone deacetylase HDAC inhibitor 61 acadesine 61 Optical Coherence Tomography 61 Factor VIIa 61 DermTech International 61 oral ghrelin agonist 61 Alfacell proprietary ribonuclease 61 radiotherapeutic 61 Trimesta 61 targeted antifolate 61 LNP formulations 61 Myocardial Perfusion Imaging 61 subcutaneous immunoglobulin 61 Preclinical Study 61 seliciclib CYC# 61 midstage trials 61 Novasome R 61 Symadex 61 PEGPH# 61 Tectin TM 61 novel immunotherapies 61 Homspera TM 61 urocortin 2 61 acyclovir Lauriad ® 61 Annamycin 61 midstage clinical 61 Personalized Immunotherapy 61 NeuroSTAT ® 61 pharmacodynamic profiles 61 cilengitide 61 Trodusquemine 61 preclinical pharmacology 61 vivo 61 Phase #b/#a trial 61 Nanobodies ® 61 Enkephalin 61 novel synthetic peptide 61 INS# [001] 61 immunotherapeutic approaches 61 microRNA profiling 61 Dr. Gabriel Lasala 61 antibody MAb 61 PrevOnco 61 omacetaxine mepesuccinate 61 receptor tyrosine kinase inhibitor 61 cytokine refractory 61 anticancer therapeutics 61 IIa trials 61 phase Ib 61 GRN# 61 pan HDAC inhibitor 60 flow cytometric 60 ZFP Therapeutics 60 Phase 1b trial 60 selective androgen receptor modulator 60 GRNCM1 60 antiangiogenic agents 60 Romidepsin 60 DUROS 60 peptide conjugated 60 Spiegelmer ® 60 pharmacophore 60 vitro experiments 60 mda 7 60 TQT studies 60 Ozarelix 60 thalidomide Thalomid 60 optical biosensors 60 CCX# 60 IAP inhibitor 60 QTinno 60 Bruton tyrosine kinase Btk 60 thetreatment 60 NSABP B 60 Enhanze Technology 60 R roscovitine 60 histamine dihydrochloride 60 ALN HTT 60 hypoxia activated prodrug 60 inhalation toxicology 60 Arcelis ™ 60 ALN TTR 60 Anticalin ® 60 mouse xenograft 60 cathepsin K inhibitor 60 Initiate Phase 60 HCV protease inhibitors 60 Vascugel ® 60 TKB# 60 Zemplar Capsules 60 IMiDs ® 60 Bioral 60 potently inhibited 60 radiotracers 60 dose escalation clinical 60 GMX# 60 Immunotherapeutic 60 Anavex #-# 60 selective immunoproteasome inhibitor 60 IIa clinical trials 60 selective kinase inhibitor 60 biased ligand 60 Anticalins ® 60 TRO# 60 triphendiol 60 IND enabling 60 BCR ABL inhibitors 60 registrational Phase 60 dosing cohort 60 CTAP# Capsules 60 VitiGam 60 Protexia ® 60 pharmacodynamic profile 60 TLR9 agonist 60 intranasal delivery 60 deCODE chemistry 60 histone deacetylase HDAC 60 Myolimus 60 cystinosis patients 60 Adaptive Radiation Therapy 60 telomerase inhibitor drug 60 delafloxacin 60 MelaFind R 60 PK PD 60 Aurora kinase inhibitors 60 anti infective treatments 60 radiolabeled TM# 60 Phase #b/#a 60 Curaxin CBLC# 60 Completes Patient Enrollment 60 vivo efficacy 60 Pre RELAX AHF 60 targeting CD# 60 Exherin TM 60 Monoclonal Antibody 60 phase IIb study 60 EZN 60 gamma secretase inhibitor 60 mutational analysis 60 Phase IIA 60 pharmacokinetic studies 60 intradermal injections 60 NuroPro PD 60 candidate CRLX# 60 sd rxRNA compounds 60 ANAVEX #-# [002] 60 Kamada AAT 60 Novolimus 60 trastuzumab Herceptin R 60 non nucleoside HCV 60 thorough QT 60 proteomic biomarkers 60 erlotinib Tarceva ® 60 epoetin zeta 60 Kinase Inhibitors 60 EV# vaccine 60 phase IIb III 60 EGFR HER2 60 flavopiridol 60 Neo Bladder Augment 60 metabolomic profiling 60 recombinant antibodies 60 PhG alpha 1 60 vascular disrupting agent 60 metabonomics 60 INOmax R 60 viral kinetics 60 PI3K/mTOR 60 phase IIa clinical 60 BACcel 60 Locked Nucleic Acid LNA 60 GVAX ® 60 AMPK activators 60 Cand5 60 Nanobody ® 60 Virulizin ® 60 metaglidasen 60 HepDirect R 60 Regenerative Cell 60 Vaxfectin 60 molecular biomarkers 60 GLPG# 60 VERSANT 60 evaluating tivozanib 60 humanized monoclonal 60 novel peptides 60 polycythemia vera PV 60 Pegylated Interferon 60 Tumorgraft 60 potent antiproliferative 60 Phase IIb III 60 Proellex TM 60 BCR ABL inhibitor 60 Multimeric 60 farletuzumab 60 CINQUIL 60 miRview meso 60 vitro cytotoxicity 60 Zybrestat 60 dasatinib Sprycel 60 xenograft 60 pharmacokinetic characteristics 60 systemic RNAi therapeutic 60 Oncotype DX colon cancer 60 Dr. Sosne 60 ResponseDX ™ 60 forodesine 60 transfection reagents 60 HuMax EGFr 60 Bevasiranib 60 miRview ™ squamous 60 personalized immunotherapy 60 NS5A inhibitor 60 dose proportionality 60 synDNA 60 Cethrin R 60 AIR2 Trial 60 aerosolized KL4 surfactant 60 CCR5 mAb 60 accumulate preferentially 60 Curaxin 60 HIV integrase inhibitors 60 antisense inhibitor 60 vascular disrupting agents 60 MEK inhibitor RDEA# 60 Tarvacin TM 60 perifosine KRX 60 Aplidin 60 ADME PK 60 lipid nanoparticle 60 Talotrexin 60 Liposomal 60 RAS MAPK pathway 60 Interferon Alpha 60 Prof. Gozes 60 VBLOC TM 60 Phase #/#a trial 60 BEZ# 60 LB# [003] 60 PERSEUS clinical program 60 immatics 60 TLK# 60 lymphoid malignancies 60 Onalta TM 60 Inhalation Solution 60 Geron telomerase inhibitor 60 molecular chaperone regulation 60 afamelanotide 60 trastuzumab DM1 60 Kinase Inhibitor 60 ALN PCS 60 CA9 SCAN 60 Pancreate 60 CHAMPION PCI 60 BFPET 59 Affymetrix GeneChip ® 59 R#/MEM 59 DepoVax ™ 59 Rigel R# 59 CEQ# 59 Pharmacodynamic 59 5 fluorouracil leucovorin 59 eligen 59 sd rxRNA 59 infantile NCL 59 humanized monoclonal antibodies 59 receptor antagonism 59 TELINTRA R 59 diagnostic molecular imaging 59 product platforms AZX# 59 SNALP technology 59 Janus Kinase 59 RenaZorb TM 59 XL# XL# 59 maturation inhibitor 59 OXIGON 59 Protein Expression 59 Evoltra ® 59 Pancreas Cancer Vaccine 59 NEUGENE R 59 2 inhibitor CYT# 59 OvaRex ® MAb 59 PSN# [002] 59 HepaMate 59 tiapamil 59 phase IIa 59 DCVax ® 59 intravesical instillation 59 highly selective endothelin 59 toenail onychomycosis 59 anti CD3 59 fusion enhancers 59 MGd 59 Triapine R 59 Tr DNA 59 immuno modulatory 59 ImmuKnow R 59 VEGFR2 inhibitor 59 cynomolgus monkeys 59 anticoagulant reversing agent 59 topically applied SEPA 59 azilsartan medoxomil 59 tolerability pharmacokinetics 59 peptidomimetic 59 clinical pharmacology studies 59 TAKSTA 59 oral renin inhibitor 59 KL4 surfactant 59 biochemical assays 59 anti CD# antibodies 59 RhuDex ® 59 bioequivalency 59 immuno therapeutic 59 proteasome inhibitor 59 proteomic analyzes 59 vaccine GRNVAC1 59 Hedgehog inhibitor 59 Hedgehog pathway inhibitor 59 Triapine 59 Capsulution 59 #F FDG PET 59 transdermal gel 59 antisense inhibition 59 Hedgehog antagonist 59 biologic therapeutics 59 cartilage regeneration 59 targeted anticancer therapies 59 Antiangiogenic 59 LHRH antagonists 59 Tarvacin Anti Cancer 59 selective androgen receptor modulators 59 Xelox 59 budesonide foam 59 tkRNAi 59 Metabolic Disease 59 Alocrest 59 Afatinib 59 Phase #/#a clinical 59 PTH analogue 59 AzaSite Plus 59 Panzem ® 59 RhuDex 59 Cyclosert TM 59 Preclinical studies 59 PNT# 59 biotherapy 59 SR# [004] 59 Phase IIB 59 JAK inhibitor 59 compound AEZS 59 translational genomics 59 EC Cysteamine 59 ADME 59 Zoraxel 59 EOquin TM 59 davunetide intranasal AL 59 Smac mimetics 59 Vascugel R 59 Xanafide 59 concurrent chemoradiation 59 Phase 2b Clinical Trial 59 nutrigenomic 59 PICM 59 Small Molecule 59 POTELLIGENT ® 59 ERYtech Pharma 59 teriflunomide 59 DepoVax TM 59 SYN# 59 radiation dosimetry 59 KL4 Surfactant 59 PNP inhibitor 59 OHR/AVR# 59 epoetin alpha 59 Vaxfectin R 59 multiplex assays 59 peptide synthesis 59 JAK#/JAK# inhibitor CYT# 59 vivo experiments 59 Moli# 59 vivo pharmacology services 59 molecular imaging radiopharmaceuticals 59 DDP# 59 Cloretazine 59 VIBEX MTX 59 Phase 2a trial 59 Alexza Staccato 59 microtubule inhibitor 59 ALGRX 59 syngeneic 59 Phase III Clinical Trials 59 CLORETAZINE TM VNP#M 59 HuMax 59 SIX RO ROG 59 phosphatidylserine PS targeting 59 pharmacogenomic translational research 59 Aurora kinase inhibitor 59 orally bioavailable 59 transcranial Doppler ultrasound 59 wilate ® 59 European Sepsis Trial 59 EECP R 59 Phase IIa proof 59 Thiovir 59 biocatalytic 59 neratinib 59 miRNA biomarkers 59 vitro dissolution 59 diagnostic biomarker 59 NOD mouse 59 #I TM# 59 GIPET 59 Angiocept 59 siRNAs targeting 59 protein electrophoresis 59 Epigenomics proprietary 59 ganaxolone 59 IMPDH inhibitor 59 Novo TTF 59 tumorigenicity 59 LT NS# 59 mGluR5 negative 59 vitro assay 59 Cytochrome P# 59 small molecule activators 59 Systemic Delivery 59 Phase lll 59 rFSH 59 enzyme immunoassay EIA 59 Sapacitabine 59 pharmacokinetic PK profile 59 AERx ® 59 alpha antagonist 59 Vidofludimus 59 tumor vascular disrupting 59 basal bolus regimen 59 Pharmacokinetic parameters 59 miconazole Lauriad ® 59 FOLFOX6 chemotherapy regimen 59 LEUKINE 59 Cx# [002] 59 inhibitor RG# 59 Canvaxin TM 59 Interferon alpha 59 Sample Processor 59 randomized controlled Phase 59 bioengineered tissue 59 lenalidomide Revlimid R 59 OnDose TM 59 NovaBay Aganocide compounds 59 Demonstrates Potential 59 immune modulatory 59 genomic proteomic 59 Cervista HPV HR 59 LHRH receptor positive 59 selective modulator 59 Ceragenin ™ 59 MedPulser 59 biodistribution studies 59 experimental autoimmune encephalomyelitis 59 humanized antibodies 59 therapeutics diagnostics 59 SinuNase ™ 59 protein kinase inhibitors 59 receptor inhibitor 59 adult mesenchymal stem 59 oral COTI 59 Xcellerated T Cells 59 pharmacodynamic effects 59 small molecule tyrosine 59 prostone 59 multiplex assay 59 vitro toxicology 59 antiangiogenic agent 59 Affimed Therapeutics AG 59 Nonclinical 59 radiolabelled 59 TRIOLEX ™ 59 GI motility disorders 59 murine model 59 CIPN 59 MOZOBIL 59 Carfilzomib 59 BiTE R 59 metastatic neuroendocrine tumors 59 FDG-PET/CT 59 GERD migraine headaches 59 refractory chronic lymphocytic 59 nucleic acid isolation 59 Aganocide ® 59 Vaxfectin R adjuvant 59 REGN# 59 Valtropin 59 dotLab System 59 iCell Cardiomyocytes 59 RhuDex R 59 PKC# 59 gastrointestinal motility disorders 59 GW# [003] 59 Tesetaxel 59 dyskinesia PD LID 59 Rosetta Genomics microRNA 59 phase IIIb 59 bazedoxifene conjugated estrogens 59 DCVax R 59 IMA# 59 bioimaging 59 RAV# 59 Selective Electrochemical Tumor Ablation 59 Phase Ib Clinical Trial 59 Aptamer 59 Cloretazine ® 59 investigational therapies 59 Intravitreal 59 Nanobody 59 Fenretinide 59 immune modulating 59 topoisomerase II inhibitor 59 Inotek Pharmaceuticals Corporation 59 pain palliation 59 GeneSightRx 59 Phase IIa 59 Initiated Phase 59 Oral Insulin 59 NSCLC tumors 59 Nasulin ™ 59 docetaxel Taxotere ® 59 MabThera rituximab 59 MVA MUC1 IL2 59 DxC #i 59 maximally tolerated dose 59 Pharmos pipeline 59 EGFR HER 59 candidate deforolimus 59 bevacizumab Avastin ® 59 neuroprotective effects 59 small molecule agonists 59 Phase 2a Trial 59 vapreotide acetate 59 neuronal nicotinic receptor NNR 59 SNT MC# 59 Pyridorin 59 Phase #/#a 59 PROSTVAC TM 59 nucleoside analog 59 Phase IIIb clinical 59 recurrent metastatic ovarian cancer 59 NuMimetic TM 59 allosteric modulation 59 immunomodulatory therapy 59 RezularTM 59 novel immunotherapeutic 58 Accium 58 oral Hsp# inhibitor 58 CDK inhibitor 58 intravenous immunoglobulin IVIG 58 bortezomib Velcade 58 pDNA vaccine 58 platinum chemotherapeutic 58 TOCOSOL Camptothecin 58 endothelin antagonist 58 cancer immunotherapies 58 SQiDworks 58 adipose derived stem cell 58 humanised monoclonal antibody 58 RECOTHROM R 58 CINtec R 58 BGC# 58 Surfactant Replacement Therapy 58 Celator 58 humanised antibody 58 EP #R 58 adipiplon 58 #T# L1 58 Initiates Phase II 58 ALN HPN 58 NYSE Amex PBTH 58 Prodarsan 58 ADME Tox 58 RRM1 58 optimal dosing regimens 58 EndoTAG TM 58 Intravail ® 58 include ColorectAlert TM 58 dimeglumine 58 ALN TTR# 58 protein biochip 58 muscarinic receptor agonist 58 radiolabeling 58 Trofex TM 58 lucinactant 58 Augment TM 58 amyloid imaging 58 SMT C# 58 BiTE 58 JAK2 inhibitors 58 transthyretin TTR mediated amyloidosis 58 KNS # 58 lintuzumab SGN 58 INSPIRE Trial Phase III 58 Drug Formulation 58 dose melphalan 58 phase IIb trial 58 Receives Orphan Drug Designation 58 Litx 58 Visit www.BASInc.com 58 oligonucleotide therapeutics 58 Juvaris BioTherapeutics 58 oral taxane 58 rALLy 58 DCE MRI 58 miRview TM 58 anti CD3 antibody 58 Inosine 58 Pivotal Phase III 58 SuperAntibody 58 AeroLEF TM 58 NMDA antagonists 58 TLR agonists 58 OncoVEX GM CSF 58 LEVADEX ™ 58 Camptothecin 58 Chemophase 58 trial evaluating PRX# 58 pharmacogenetic testing 58 biomarker identification 58 Recombinant Human 58 AAV vectors 58 NEUGENE 58 SinuNase TM 58 rALLy clinical trial 58 theranostic 58 assessing T DM1 58 e2 Collector 58 Simulect 58 DNA methyltransferase inhibitors 58 systemically administered 58 novel radiopharmaceuticals 58 Clinical Validation 58 ImmunoGen TAP technology 58 Gastrointestinal Stromal Tumors 58 recombinant PSMA vaccine 58 PsychoGenics 58 matrix metalloproteases 58 MAGE A3 ASCI 58 OMNARIS HFA 58 MDRNA proprietary 58 randomized discontinuation 58 Gleevec imatinib mesylate 58 Preclinical Data 58 DGAT1 inhibitors 58 throughput RNAi 58 OncoVEX 58 oral rivaroxaban 58 verteporfin 58 HDAC Inhibitor 58 EndoTAG TM -1 58 Cytori Celution System 58 DMPK 58 ZFP TF 58 MAb 58 DGAT 58 indibulin 58 Panzem 58 Solorel TM 58 GelSite polymer 58 pharmacokinetics PK 58 lumiliximab 58 JAK1 58 Aurora Kinase 58 RONDEL ™ 58 TransVax TM 58 INTERCEPT platelets 58 Western Blotting 58 synDNA TM 58 anti HAAH antibodies 58 Bioral ® 58 porcine derived 58 Pentad TM 58 TPI ASM8 58 pharmacodynamic markers 58 TRX1 58 thymosin beta 4